www.hivandhepatitis.com

IAS 2017: WHO Recommends Urgent Care Package for People with Advanced HIV Disease

A new package of measures to ensure rapid initiation of antiretroviral treatment and diagnosis of opportunistic infections has been recommended by the World Health Organization (WHO) to reduce the still high rates of death among people diagnosed with HIV at a very advanced stage of disease.

Read more:

IAS 2017: Study of Gay Men Shows No Transmissions from Undetectable HIV+ Partners

A study of 343 gay couples, where one partner had HIV and the other did not, has not found a single case of HIV transmission in 16,889 acts of condomless anal sex, according to a presentation at the 9th International AIDS Society Conference on HIV Science (IAS 2017) this week in Paris.

Read more:

IAS 2017: Improved Cryptococcal Meningitis Treatment Could Save Thousands of Lives

Urgent action is needed to improve access to the antifungal drug flucytosine, say investigators, following the presentation of the results of a trial showing that treatment containing flucytosine is superior to any other form of therapy in reducing the risk of death from cryptococcal meningitis in people with very advanced HIV disease.

Read more:

IAS 2017: Long-Acting Cabotegravir + Rilpivirine Looks Good for HIV ART

Two long-acting injectable antiretrovirals, cabotegravir and rilpivirine, administered once every 4 or 8 weeks maintained viral suppression in about 90% of people who started therapy with an undetectable viral load, according to the latest results from the LATTE-2 trial, presented at the 9th International AIDS Society Conference on HIV Science this week in Paris and published simultaneously in The Lancet.

Read more:

Coverage of the 2017 IAS Conference on HIV Science

HIVandHepatitis.com coverage of the 9th International AIDS Society Conference on HIV Science, July 23-26, 2017, in Paris.

Full coverage listing by topic

IAS 2017 website

7/31/17

IAS 2017: New HIV Integrase Inhibitor Bictegravir Works Well for First-Line Treatment

A single-tablet regimen containing the experimental integrase inhibitor bictegravir was as effective as 2 widely used approved regimens for first-time therapy in a pair of Phase 3 clinical trials, according to presentations at the 9th International AIDS Society Conference on HIV Science (IAS 2017) this week in Paris.

Read more:

Coverage of the 2017 IAS Conference on HIV Science

HIVandHepatitis.com coverage of the 9th International AIDS Society Conference on HIV Science, July 23-26, 2017, in Paris.

Antiretroviral Therapy

• Doravirine Combo Pill Looks Good for Initial HIV Treatment
• Boosted Darunavir Plus Lamivudine Matches 3-Drug Regimen
• Trans Women Wary of Antiretroviral Drug and Hormone Interactions
• Novel Long-Acting Drug Shows Promise for HIV Treatment and PrEP
• First Protease Inhibitor Combo Pill Maintains Viral Suppression
• Long-Acting Cabotegravir + Rilpivirine Looks Good for HIV ART
• New HIV Integrase Inhibitor Bictegravir Works Well for First-Line Treatment IAS

HIV Cure Research

• Cancer Research May Offer Clues for HIV Cure Research -- and Vice Versa
• Why Curing Cancer May Be Like Curing HIV -- and May Be As Difficult
• VRC01 Antibody Can Delay But Not Prevent HIV Rebound
• South African Child Has Controlled HIV Off Treatment for 8.5 Years

HIV Prevention

• Experts Agree that Intermittent Oral PrEP Probably Won't Work for Women
• Who Are Trans Women Acquiring HIV From?
• PrEP Use in U.S. Exceeds 100,000 in Gilead Pharmacy Survey
• Medical Male Circumcision for HIV Prevention Has Benefits for Women Too
• Another HIV Vaccine Efficacy Trial Will Start This Year
• Demonstration Projects Explore Feasibility of PrEP for Adolescents in South Africa
• Study of Gay Couples Shows No Transmissions from Undetectable HIV+ Partners
• Long-Acting Cabotegravir Shows Promise For HIV Prevention
• PrEP Still Protected People Who Had Less Sex in Ipergay Study

HIV-Related Conditions and Comorbidities

• Switch from Boosted Protease Inhibitor to Dolutegravir Reduces Lipids in People with HIV
• Acute Kidney Injury Uncommon on Tenofovir, No Link Seen to Bone Breaks
• People with HIV Are at Risk for Liver Fibrosis and Steatosis

HIV Epidemiology and Access to Care

• Aim for $90-$90-$90 Target on HIV, Hepatitis, and TB Drug Prices, Study Says
• Improved Cryptococcal Meningitis Treatment Could Save Thousands of Lives
• WHO Recommends Urgent Care Package for People with Advanced HIV Disease
• World On Track To Reach 90-90-90 Targets for HIV Treatment by 2020
• New HIV Infections Halved as Treatment Scales Up in Swaziland

Hepatitis C and HIV/HCV Coinfection

• Glecaprevir/Pibrentasvir Effective for People with HIV/HCV Coinfection
• Hepatitis C Treatment is Effective and Feasible in Africa

IAS 2017: World On Track To Reach 90-90-90 Targets for HIV Treatment by 2020

The world is on track to reach global targets for reducing AIDS deaths and expanding HIV treatment access by 2020, but some regions of the world risk falling further behind due to lack of political commitment, UNAIDS announced in the run-up tothe 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris.

Read more: